VRTX Vertex Pharmtgt upped to $58 at Piper Jaffray (43.96 )
Piper Jaffray raises their VRTX tgt to $58 from $42 based on taking a closer look at the potential market opportunity for VRTX's HCV protease inhibitor telaprevir.
Know how to make God laugh? Tell Her your plans ....